Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Net Cash Flow (2019 - 2025)

Revolution Medicines has reported Net Cash Flow over the past 7 years, most recently at $166.3 million for Q4 2025.

  • Quarterly results put Net Cash Flow at $166.3 million for Q4 2025, down 51.46% from a year ago — trailing twelve months through Dec 2025 was -$158.2 million (down 3.77% YoY), and the annual figure for FY2025 was -$158.2 million, down 3.77%.
  • Net Cash Flow for Q4 2025 was $166.3 million at Revolution Medicines, up from -$184.1 million in the prior quarter.
  • Over the last five years, Net Cash Flow for RVMD hit a ceiling of $342.6 million in Q4 2024 and a floor of -$407.7 million in Q1 2024.
  • Median Net Cash Flow over the past 5 years was -$15.1 million (2022), compared with a mean of $14.2 million.
  • Peak annual rise in Net Cash Flow hit 2554.39% in 2023, while the deepest fall reached 667.35% in 2023.
  • Revolution Medicines' Net Cash Flow stood at -$20.0 million in 2021, then rose by 12.37% to -$17.5 million in 2022, then surged by 2030.45% to $338.4 million in 2023, then rose by 1.25% to $342.6 million in 2024, then crashed by 51.46% to $166.3 million in 2025.
  • The last three reported values for Net Cash Flow were $166.3 million (Q4 2025), -$184.1 million (Q3 2025), and $69.1 million (Q2 2025) per Business Quant data.